FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Epie Boven

Research Profile

Living Beings

Disorders

Chemicals & Drugs

Procedures

Anatomy

Tumor Cells, Cultured

Physiology

Cell Divisions

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Marc Warmoes; Guotai Xu; Epie Boven; Janneke E Jaspers; Jos Jonkers; Jaco C Knol; Thang V Pham; Sander R Piersma; Sven Rottenberg; Bharath K Sampadi; Connie R Jimenez
Proteomics of genetically engineered mouse mammary tumors identifies Fatty Acid metabolism members as potential predictive markers for Cisplatin resistance.
Michiel B de Ruiter; Gwenaëlle Douaud; Cristina Lavini; Sabine C Linn; Liesbeth Reneman; Willem Boogerd; Epie Boven; Matthan Caan; Frits S A M van Dam; Dick J Veltman; Sanne B Schagen
Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging.
Saskia F A Duijts; Maud M Geenen; Miranda A Gerritsma; Gijsbert Heuff; Myra S Hunter; Jacobien M Kieffer; Alexander M F Lopes Cardozo; Marian B E Menke-Pluymers; Hester S A Oldenburg; Peter W Plaisier; Herman Rijna; Martijn M Stuiver; Gertjan Timmers; Marc van Beurden; Suzan van der Meij; Henk van der Veen; Eric J van Dulken; Nina Bijker; Epie Boven; Louise M de Widt-Levert; Neil K Aaronson
Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Epie Boven (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Marc Warmoes; Guotai Xu; Epie Boven; Janneke E Jaspers; Jos Jonkers; Jaco C Knol; Thang V Pham; Sander R Piersma; Sven Rottenberg; Bharath K Sampadi; Connie R Jimenez
Proteomics of genetically engineered mouse mammary tumors identifies Fatty Acid metabolism members as potential predictive markers for Cisplatin resistance.
Molecular & cellular proteomics : MCP 2013;12(5):1319-34.
2012: Michiel B de Ruiter; Gwenaëlle Douaud; Cristina Lavini; Sabine C Linn; Liesbeth Reneman; Willem Boogerd; Epie Boven; Matthan Caan; Frits S A M van Dam; Dick J Veltman; Sanne B Schagen
Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging.
Human brain mapping 2012;33(12):2971-83.
2012: Saskia F A Duijts; Maud M Geenen; Miranda A Gerritsma; Gijsbert Heuff; Myra S Hunter; Jacobien M Kieffer; Alexander M F Lopes Cardozo; Marian B E Menke-Pluymers; Hester S A Oldenburg; Peter W Plaisier; Herman Rijna; Martijn M Stuiver; Gertjan Timmers; Marc van Beurden; Suzan van der Meij; Henk van der Veen; Eric J van Dulken; Nina Bijker; Epie Boven; Louise M de Widt-Levert; Neil K Aaronson
Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(33):4124-33.
2012: Joost S Vermaat; Jos H Beijnen; Epie Boven; Frank L Gerritse; Jourik A Gietema; John B Haanen; Tatjana M Niers; Sjoukje F Oosting; Dick J Richel; Wijnand M Roessingh; Jeanine M Roodhart; Jan H Schellens; Stefan Sleijfer; Astrid A van der Veldt; Emile E Voest
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
European urology 2012;62(4):685-95.
2012: Lonneke Timmers; Myrthe P P van Herk-Sukel; Jan Jacob Beckeringh; Epie Boven; Jacqueline G Hugtenburg
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.
Pharmacoepidemiology and drug safety 2012;21(10):1036-44.
2012: Astrid A M van der Veldt; Victor W M van Hinsbergh; Laura Vroling; Henk J Broxterman; Richard R de Haas; John B A G Haanen; PIETER KOOLWIJK; Alfons J M van den Eertwegh; Epie Boven
Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer.
International journal of cancer. Journal international du cancer 2012;131(4):E484-93.
2012: Marc Warmoes; Epie Boven; Janneke E Jaspers; Jos Jonkers; Maarten P G Massink; Gideon Oudgenoeg; Thang V Pham; Sander R Piersma; Sven Rottenberg; Quinten Waisfisz; Connie R Jimenez
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
Molecular & cellular proteomics : MCP 2012;11(7):M111.013334.
2012: Lonneke Timmers; Peter M van de Ven; Christel Clm Boons; Epie Boven; Dirk Mangnus; Godefridus J Peters; Eleonora L Swart; Jacqueline G Hugtenburg
The use of capecitabine in daily practice: a study on adherence and patients' experiences.
Patient preference and adherence 2012;6():741-8.
2012: Jetske Ruiterkamp; Emiel J Th Rutgers; Vivianne C G Tjan-Heijnen; Yvette M van der Linden; Maurice J C van der Sangen; Adri C Voogd; Koop Bosscha; Epie Boven; Miranda F Ernst
SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation.
BMC surgery 2012;12():5.
2011: R W F van Leeuwen; F A Boom; Epie Boven; M G Schuitenmaker; Eleonora L Swart; Jacqueline G Hugtenburg
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(10):2334-41.
2011: Michiel B de Ruiter; Aart J Nederveen; Liesbeth Reneman; Willem Boogerd; Epie Boven; Frits S A M van Dam; Dick J Veltman; Sanne B Schagen
Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.
Human brain mapping 2011;32(8):1206-19.
2010: Astrid A M van der Veldt; John B A G Haanen; Alfons J M van den Eertwegh; Epie Boven
Targeted therapy for renal cell cancer: current perspectives.
Discovery medicine 2010;10(54):394-405.
2010: Maurice J D L van der Vorst; Maaike C G Bleeker; Epie Boven
Unusual presentation of granulosa cell tumor of the ovary.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):e554-6.
2010: Martijn R Meijerink; Jan-Hein T M van Waesberghe; Cors van Schaik; Epie Boven; Astrid A M van der Veldt; Petrousjka van den Tol; Sybren Meijer; Cornelis van Kuijk
Perfusion CT and US of colorectal cancer liver metastases: a correlative study of two dynamic imaging modalities.
Ultrasound in medicine & biology 2010;36(10):1626-36.
2010: Epie Boven; C Massard; J P Armand; C Tillier; V Hartog; N M Brega; A M Countouriotis; A Ruiz-Garcia; J C Soria
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
British journal of cancer 2010;103(7):993-1000.
2010: Judith R Kroep; S C Linn; Epie Boven; H J Bloemendal; J Baas; I A M Mandjes; J van den Bosch; W M Smit; H de Graaf; C P Schröder; G J Vermeulen; W C J Hop; J W R Nortier
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
The Netherlands journal of medicine 2010;68(9):371-6.
2010: Nielka P H van Erp; Ron H J Mathijssen; A A van der Veldt; J B Haanen; A K L Reyners; K Eechoute; Epie Boven; J A M Wessels; Henk-Jan Guchelaar; Hans Gelderblom
Myelosuppression by sunitinib is flt-3 genotype dependent.
British journal of cancer 2010;103(5):757-8.
2010: Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Targeted therapies in renal cell cancer: recent developments in imaging.
Targeted oncology 2010;5(2):95-112.
2010: Axel Bex; Astrid A M van der Veldt; Christian Blank; Martijn R Meijerink; Epie Boven; John B A G Haanen
Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
Acta oncologica (Stockholm, Sweden) 2010;49(4):520-3.
2010: Axel Bex; Astrid A M van der Veldt; Epie Boven; John B A G Haanen
Re: Surgical resection of renal cell carcinoma after targeted therapyA. A. Thomas, B. I. Rini, A. J. Stephenson, J. A. Garcia, A. Fergany, V. Krishnamurthi, A. C. Novick, I. S. Gill, E. A. Klein, M. Zhou and S. C. Campbell J Urol 2009; 182: 881-886.
The Journal of urology 2010;183(4):1646-7; author reply 1647.
2010: Astrid A M van der Veldt; Michiel P de Boer; Epie Boven; Etto C Eringa; Alfons J M van den Eertwegh; Victor W van Hinsbergh; Yvo M Smulders; Erik H Serné
Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib.
Anti-cancer drugs 2010;21(4):439-46.
2010: Astrid A M van der Veldt; M R Meijerink; Alfons J M van den Eertwegh; John B A G Haanen; Epie Boven
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
British journal of cancer 2010;102(5):803-9.
2009: Nielka P van Erp; Karel Eechoute; Astrid A van der Veldt; John B Haanen; An K L Reyners; Ron H J Mathijssen; Epie Boven; Tahar van der Straaten; Renée F Baak-Pablo; Judith A M Wessels; Henk-Jan Guchelaar; Hans Gelderblom
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4406-12.
2009: Astrid A M van der Veldt; Epie Boven; Axel Bex
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523.
The Journal of urology 2009;182(2):797; author reply 797-8.
2009: Axel Bex; Astrid A M van der Veldt; Christian Blank; Alfons J M van den Eertwegh; Epie Boven; Simon Horenblas; John Haanen
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
World journal of urology 2009;27(4):533-9.
2009: Marcel N A Bijman; Maria P A van Berkel; Mirjam Kok; Maarten L Janmaat; Epie Boven
Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
Anti-cancer drugs 2009;20(6):450-60.
2009: Astrid A M van der Veldt; Epie Boven; Laura Vroling; Henk J Broxterman; Alfons J M van den Eertwegh; John G Haanen
Sunitinib-induced hemoglobin changes are related to the dosing schedule.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(8):1339-40; author reply 1340-2.
2009: Inge Saskia van Houdt; Berbel J R Sluijter; Paul A M van Leeuwen; L M Moesbergen; Erik Hooijberg; C J L M Meijer; Tanja D de Gruijl; Joost Oudejans; Epie Boven
Absence of Granzyme B positive tumour-infiltrating lymphocytes in primary melanoma excisional biopsies is strongly associated with the presence of sentinel lymph node metastasis.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2009;31(5):407-13.
2009: Dennis Fontijn; Linda J W Bosch; Monique C A Duyndam; Maria P A van Berkel; Maarten L Janmaat; Epie Boven
Basic fibroblast growth factor-mediated overexpression of vascular endothelial growth factor in 1F6 human melanoma cells is regulated by activation of PI-3K and p38 MAPK.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2009;31(3):179-90.
2009: Laura Vroling; Astrid A M van der Veldt; Richard R de Haas; John B A G Haanen; Gerrit Jan Schuurhuis; Dirk J Kuik; Hester van Cruijsen; Hendrik Verheul; Alfons J M van den Eertwegh; Klaas Hoekman; Epie Boven; Victor W M van Hinsbergh; Henk J Broxterman
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Angiogenesis 2009;12(1):69-79.
2008: Hester van Cruijsen; Astrid A M van der Veldt; Laura Vroling; Dinja Oosterhoff; Henk J Broxterman; Rik J Scheper; Giuseppe Giaccone; John B A G Haanen; Alfons J M van den Eertwegh; Epie Boven; Klaas Hoekman; Tanja D de Gruijl
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5884-92.
2008: Marcel N A Bijman; Maria P A van Berkel; Geerten P van Nieuw Amerongen; Epie Boven
Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility.
Biochemical pharmacology 2008;76(6):707-16.
2008: Rutger W H M Staffhorst; Kasper van der Born; Caroline A M Erkelens; Irene H L Hamelers; Godefridus J Peters; Epie Boven; Anton I P M de Kroon
Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
Anti-cancer drugs 2008;19(7):721-7.
2008: Astrid A M van der Veldt; Epie Boven; H H Helgason; M van Wouwe; Johannes Berkhof; G de Gast; H Mallo; C N Tillier; Alfons J M van den Eertwegh; John B A G Haanen
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
British journal of cancer 2008;99(2):259-65.
2008: Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Axel Bex; Gijsbert de Gast; John B A G Haanen; Epie Boven
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2431-6.
2008: Aart Beeker; Epie Boven; Pierre Lefesvre; Richard P Golding; Cees J van Groeningen
Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinoma.
International journal of clinical oncology 2008;13(1):71-3.
2008: Marcel N A Bijman; Cristian A Hermelink; Maria P A van Berkel; Adrie C Laan; Maarten L Janmaat; Godefridus J Peters; Epie Boven
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Biochemical pharmacology 2008;75(2):427-37.
2008: Helgi H Helgason; Henk A Mallo; Helga Droogendijk; John G Haanen; Astrid A M van der Veldt; Alfons J M van den Eertwegh; Epie Boven
Brain metastases in patients with renal cell cancer receiving new targeted treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):152-4.
2007: Dennis Fontijn; Auke D Adema; Kishor K Bhakat; HERBERT PINEDO; Godefridus J Peters; Epie Boven
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Molecular cancer therapeutics 2007;6(10):2807-15.
2007: Astrid A M van der Veldt; Alfons J M van den Eertwegh; K Hoekman; F Barkhof; Epie Boven
Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(10):1747-50.
2007: Laura Vroling; Yuana Yuana; Gerrit J Schuurhuis; Victor W M van Hinsbergh; Chad Gundy; Richard de Haas; Hester van Cruijsen; Epie Boven; Klaas Hoekman; Henk J Broxterman
VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients.
Thrombosis and haemostasis 2007;98(2):440-50.
2007: Monique C A Duyndam; Maria P A van Berkel; Josephine C Dorsman; Davy A P Rockx; HERBERT PINEDO; Epie Boven
Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
Biochemical pharmacology 2007;74(2):191-201.
2007: Dennis Fontijn; Monique C A Duyndam; Jeroen A M Beliën; Marielle I Gallegoz Ruiz; HERBERT PINEDO; Epie Boven
The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis.
Melanoma research 2007;17(3):155-68.
2007: Carolien H Smorenburg; Cees J van Groeningen; O W M Meijer; M Visser; Epie Boven
Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands.
The Netherlands journal of medicine 2007;65(4):132-6.
2006: Marcel N A Bijman; Geerten P van Nieuw Amerongen; Nancy Laurens; Victor W M van Hinsbergh; Epie Boven
Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton.
Molecular cancer therapeutics 2006;5(9):2348-57.
2006: Dennis Fontijn; Monique C A Duyndam; Maria P A van Berkel; Yuana Yuana; Linda H. Shapiro; HERBERT PINEDO; Henk J Broxterman; Epie Boven
CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells.
British journal of cancer 2006;94(11):1627-36.
2005: A H G Hansma; Henk J Broxterman; I van der Horst; Yuana Yuana; Epie Boven; Giuseppe Giaccone; HERBERT PINEDO; Klaas Hoekman
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(10):1695-701.
2005: Epie Boven; Marjan J Westerman; Cees J van Groeningen; Miranda Verschraagen; Rita Ruijter; I Zegers; Wim J F van der Vijgh; Giuseppe Giaccone
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
British journal of cancer 2005;92(9):1636-43.
2004: Michelle de Graaf; Tapio J Nevalainen; Hans W Scheeren; HERBERT PINEDO; Hidde J Haisma; Epie Boven
A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
Biochemical pharmacology 2004;68(11):2273-81.
2004: Miranda Verschraagen; Epie Boven; Emine Torun; FREDERICK HAUSHEER; Aalt Bast; Wim J F van der Vijgh
Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Biochemical pharmacology 2004;68(3):493-502.
2004: N Croles; Carolien H Smorenburg; Cees J van Groeningen; Giuseppe Giaccone; Epie Boven
FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer.
The Netherlands journal of medicine 2004;62(7):242-5.
2004: Miranda Verschraagen; Epie Boven; Emine Torun; C A M Erkelens; FREDERICK HAUSHEER; Wim J F van der Vijgh
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
British journal of cancer 2004;90(8):1654-9.
2004: Michelle de Graaf; HERBERT PINEDO; Dinja Oosterhoff; Ida H van der Meulen-Muileman; Winald Gerritsen; Hidde J Haisma; Epie Boven
Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
Human gene therapy 2004;15(3):229-38.
2004: Yvette van Hensbergen; Henk J Broxterman; Sareena Rana; Paulus van Diest; Monique C A Duyndam; Klaas Hoekman; HERBERT PINEDO; Epie Boven
Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):1180-91.
2004: Gertjan J M den Hartog; Guido R M M Haenen; Epie Boven; Wim J F van der Vijgh; Aalt Bast
Lecithinized copper,zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice.
Toxicology and applied pharmacology 2004;194(2):180-8.
2003: Dinja Oosterhoff; M Adhiambo Witlox; Victor W van Beusechem; Hidde J Haisma; Gerard R Schaap; Johannes Bras; Frank A E Kruyt; Bonnie Molenaar; Epie Boven; Paul I J M Wuisman; HERBERT PINEDO; Winald Gerritsen
Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
Molecular cancer therapeutics 2003;2(8):765-71.
2003: Miranda Verschraagen; Epie Boven; Rita Ruijter; Kasper van der Born; Johannes Berkhof; FREDERICK HAUSHEER; Wim J F van der Vijgh
Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Clinical pharmacology and therapeutics 2003;74(2):157-69.
2003: Jeremy P Braybrooke; Epie Boven; Nicholas Bates; Rita Ruijter; Nicola A Dobbs; PD Cheverton; HERBERT PINEDO; Denis C Talbot
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):913-21.
2003: Michelle de Graaf; HERBERT PINEDO; Razi Quadir; Hidde J Haisma; Epie Boven
Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin.
Biochemical pharmacology 2003;65(11):1875-81.
2003: Miranda Verschraagen; Epie Boven; Ivon Zegers; FREDERICK HAUSHEER; Wim J F van der Vijgh
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Cancer chemotherapy and pharmacology 2003;51(6):525-9.
2003: Monique C A Duyndam; Saskia T M Hulscher; ELSKEN VAN DER WALL; HERBERT PINEDO; Epie Boven
Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite.
The Journal of biological chemistry 2003;278(9):6885-95.
2002: Annemarie H Van Hattum; HERBERT PINEDO; Hennie M M Schlüper; C A M Erkelens; Akiko Tohgo; Epie Boven
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
Biochemical pharmacology 2002;64(8):1267-77.
2002: Annemarie H Van Hattum; I J Hoogsteen; Hennie M M Schlüper; Marc Maliepaard; George L Scheffer; Rik J Scheper; G Kohlhagen; Y Pommier; HERBERT PINEDO; Epie Boven
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
British journal of cancer 2002;87(6):665-72.
2002: Annemarie H Van Hattum; Hennie M M Schlüper; FREDERICK HAUSHEER; HERBERT PINEDO; Epie Boven
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
International journal of cancer. Journal international du cancer 2002;100(1):22-9.
2002: Epie Boven
American Association for Cancer Research - 93rd Annual Meeting. 6-10 April 2002, San Francisco, CA, USA.
IDrugs : the investigational drugs journal 2002;5(5):403-7.
2002: Epie Boven; Miranda Verschraagen; Theresia M Hulscher; C A M Erkelens; FREDERICK HAUSHEER; HERBERT PINEDO; Wim J F van der Vijgh
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1148-56.
2002: Judith R Kroep; Willem J P Loves; Clasina L Van der Wilt; Enrique Alvarez; Iannis Talianidis; Epie Boven; Boudewijn J M Braakhuis; Cees J van Groeningen; HERBERT PINEDO; Godefridus J Peters
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Molecular cancer therapeutics 2002;1(6):371-6.
2002: Michelle de Graaf; Epie Boven; Dinja Oosterhoff; Ida H van der Meulen-Muileman; G A Huls; Winald Gerritsen; Hidde J Haisma; HERBERT PINEDO
A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
British journal of cancer 2002;86(5):811-8.
2002: Yvette van Hensbergen; Henk J Broxterman; Yvonne W Elderkamp; Jan Lankelma; Judith C C Beers; Marc Heijn; Epie Boven; Klaas Hoekman; HERBERT PINEDO
A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
Biochemical pharmacology 2002;63(5):897-908.
2002: Geertruida M Kolfschoten; Theresia M Hulscher; S M Schrier; Viola M M van Houten; HERBERT PINEDO; Epie Boven
Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Gynecologic oncology 2002;84(3):404-12.
2002: Geertruida M Kolfschoten; Theresia M Hulscher; Monique C A Duyndam; HERBERT PINEDO; Epie Boven
Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel.
Biochemical pharmacology 2002;63(4):733-43.
2002: Monique C A Duyndam; Marion C G W Hilhorst; Hennie M M Schlüper; Hendrik Verheul; Paulus van Diest; Georg Kraal; HERBERT PINEDO; Epie Boven
Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts.
The American journal of pathology 2002;160(2):537-48.
2002: Michelle de Graaf; Epie Boven; Hans W Scheeren; Hidde J Haisma; HERBERT PINEDO
Beta-glucuronidase-mediated drug release.
Current pharmaceutical design 2002;8(15):1391-403.
2001: Monique C A Duyndam; Theresia M Hulscher; Dennis Fontijn; HERBERT PINEDO; Epie Boven
Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite.
The Journal of biological chemistry 2001;276(51):48066-76.
2001: Epie Boven
American Society of Clinical Oncology - 37th Annual Meeting. Small-molecule therapeutics. 12-15 May 2001, San Francisco, CA, USA.
IDrugs : the investigational drugs journal 2001;4(8):849-52.
2001: Epie Boven
92nd AACR. Microtubule and farnesyltransferase inhibitors.
IDrugs : the investigational drugs journal 2001;4(5):511-4.
2001: Epie Boven
92nd AACR. Anti-angiogenic agents.
IDrugs : the investigational drugs journal 2001;4(5):507-10.
2001: FA van Acker; Epie Boven; Klaas Kramer; Guido R M M Haenen; Aalt Bast; Wim J F van der Vijgh
Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1378-84.
2001: PH Houba; Epie Boven; Ida H van der Meulen-Muileman; RG Leenders; JW Scheeren; HERBERT PINEDO; Hidde J Haisma
Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
International journal of cancer. Journal international du cancer 2001;91(4):550-4.
2001: PH Houba; Epie Boven; Ida H van der Meulen-Muileman; RG Leenders; JW Scheeren; HERBERT PINEDO; Hidde J Haisma
A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
British journal of cancer 2001;84(4):550-7.
2001: Epie Boven
European Society of Medical Oncology--25th anniversary meeting.
IDrugs : the investigational drugs journal 2001;4(1):30-4.
2000: Annemarie H Van Hattum; HERBERT PINEDO; Hennie M M Schlüper; FREDERICK HAUSHEER; Epie Boven
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
International journal of cancer. Journal international du cancer 2000;88(2):260-6.
2000: Geertruida M Kolfschoten; Theresia M Hulscher; HERBERT PINEDO; Epie Boven
Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
British journal of cancer 2000;83(7):921-7.
2000: Geertruida M Kolfschoten; HERBERT PINEDO; Peter G Scheffer; Hennie M M Schlüper; C A M Erkelens; Epie Boven
Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Gynecologic oncology 2000;76(3):362-8.
2000: Epie Boven; Annemarie H Van Hattum; I Hoogsteen; Hennie M M Schlüper; HERBERT PINEDO
New analogues of camptothecins. Activity and resistance.
Annals of the New York Academy of Sciences 2000;922():175-7.
1999: J Welink; Epie Boven; Jan B Vermorken; Helen Gall; Wim J F van der Vijgh
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2349-58.
1999: RG Leenders; Eric W P Damen; Edward J A Bijsterveld; Hans W Scheeren; PH Houba; Ida H van der Meulen-Muileman; Epie Boven; Hidde J Haisma
Novel anthracycline-spacer-beta-glucuronide,-beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy.
Bioorganic & medicinal chemistry 1999;7(8):1597-610.
1999: Epie Boven
American Society of Clinical Oncology--35th annual meeting. 15-18 May 1999, Atlanta, GA, USA.
IDrugs : the investigational drugs journal 1999;2(7):617-9.
1999: Epie Boven
American Association for Cancer Research--90th annual meeting. 10-14 April 1999, Philadelphia, PA, USA.
IDrugs : the investigational drugs journal 1999;2(6):530-3.
1999: Epie Boven; WJ Jansen; Theresia M Hulscher; Jos H Beijnen; O van Tellingen
The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts.
European journal of cancer (Oxford, England : 1990) 1999;35(5):840-9.
1999: PH Houba; Epie Boven; Ida H van der Meulen-Muileman; RG Leenders; JW Scheeren; HERBERT PINEDO; Hidde J Haisma
Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts.
Biochemical pharmacology 1999;57(6):673-80.
1999: Aafke H Honkoop; Sylvia A Luykx-de Bakker; Klaas Hoekman; S Meyer; O W Meyer; Cees J van Groeningen; Paulus van Diest; Epie Boven; ELSKEN VAN DER WALL; Giuseppe Giaccone; John Wagstaff; HERBERT PINEDO
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
The oncologist 1999;4(2):106-11.
1998: PH Houba; Epie Boven; C A M Erkelens; RG Leenders; JW Scheeren; HERBERT PINEDO; Hidde J Haisma
The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.
British journal of cancer 1998;78(12):1600-6.
1998: Epie Boven; HERBERT PINEDO; Annemarie H Van Hattum; Peter G Scheffer; W H Peters; C A M Erkelens; Hennie M M Schlüper; CM Kuiper; J van Ark-Otte; Giuseppe Giaccone
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.
British journal of cancer 1998;78(12):1586-93.
1998: Hidde J Haisma; M F Sernee; Erik Hooijberg; Ruud H Brakenhoff; I H vd Meulen-Muileman; HERBERT PINEDO; Epie Boven
Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
Blood 1998;92(1):184-90.
1998: J van Ark-Otte; Marc A Kedde; Wim J F van der Vijgh; AM Dingemans; WJ Jansen; HERBERT PINEDO; Epie Boven; Giuseppe Giaccone
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
British journal of cancer 1998;77(12):2171-6.
1998: AE Korst; Epie Boven; ML van der Sterre; AM Fichtinger-Schepman; Wim J F van der Vijgh
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
European journal of cancer (Oxford, England : 1990) 1998;34(3):412-6.
1998: WJ Jansen; Theresia M Hulscher; J van Ark-Otte; Giuseppe Giaccone; HERBERT PINEDO; Epie Boven
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
British journal of cancer 1998;77(3):359-65.
1998: E Kievit; FB van Gog; Hennie M M Schlüper; Guus A M S van Dongen; HERBERT PINEDO; Epie Boven
[186Re]-labeled mouse and chimeric monoclonal antibody 323/A3: a comparison of the efficacy in experimental human ovarian cancer.
Nuclear medicine and biology 1998;25(1):37-45.
1998: Hidde J Haisma; Ruud H Brakenhoff; I vd Meulen-Muileman; HERBERT PINEDO; Epie Boven
Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human beta-glucuronidase.
Cancer immunology, immunotherapy : CII 1998;45(5):266-72.
1997: WJ Jansen; Geertruida M Kolfschoten; C A M Erkelens; J van Ark-Otte; HERBERT PINEDO; Epie Boven
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
International journal of cancer. Journal international du cancer 1997;73(6):891-6.
1997: Saskia van Acker; Epie Boven; K Kuiper; D J van den Berg; JA Grimbergen; Klaas Kramer; Aalt Bast; Wim J F van der Vijgh
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1747-54.
1997: Aafke H Honkoop; ELSKEN VAN DER WALL; Nicole Feller; Gerrit J Schuurhuis; Wim J F van der Vijgh; Epie Boven; Cees J van Groeningen; Giuseppe Giaccone; Klaas Hoekman; Jan B Vermorken; John Wagstaff; HERBERT PINEDO
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):957-62.
1997: E Kievit; FB van Gog; Hennie M M Schlüper; Guus A M S van Dongen; HERBERT PINEDO; Epie Boven
Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
International journal of radiation oncology, biology, physics 1997;38(4):813-23.
1997: E Kievit; HERBERT PINEDO; Hennie M M Schlüper; Epie Boven
Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer.
International journal of radiation oncology, biology, physics 1997;38(2):419-28.
1997: E Kievit; HERBERT PINEDO; Hennie M M Schlüper; Hidde J Haisma; Epie Boven
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
International journal of cancer. Journal international du cancer 1997;71(2):237-45.
1997: WJ Jansen; B Zwart; S T Hulscher; Giuseppe Giaccone; HERBERT PINEDO; Epie Boven
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
International journal of cancer. Journal international du cancer 1997;70(3):335-40.
1997: AE Korst; Epie Boven; ML van der Sterre; AM Fichtinger-Schepman; Wim J F van der Vijgh
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
British journal of cancer 1997;75(10):1439-46.
1996: Aafke H Honkoop; Klaas Hoekman; John Wagstaff; Cees J van Groeningen; Jan B Vermorken; Epie Boven; HERBERT PINEDO
Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
British journal of cancer 1996;74(7):1132-6.
1996: PH Houba; Epie Boven; Hidde J Haisma
Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy.
Bioconjugate chemistry 1996;7(5):606-11.
1996: PH Houba; RG Leenders; Epie Boven; JW Scheeren; HERBERT PINEDO; Hidde J Haisma
Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Biochemical pharmacology 1996;52(3):455-63.
1996: Epie Boven; J de Jong; CM Kuiper; A Bast; Wim J F van der Vijgh
Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1382-7.
1996: E Kievit; HERBERT PINEDO; Hennie M M Schlüper; Hidde J Haisma; Epie Boven
Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts.
British journal of cancer 1996;73(4):457-64.
1996: Aafke H Honkoop; Klaas Hoekman; John Wagstaff; Epie Boven; Cees J van Groeningen; Giuseppe Giaccone; Jan B Vermorken; HERBERT PINEDO
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):35-9.
1995: WJ Jansen; HERBERT PINEDO; C L van der Wilt; N Feller; U Bamberger; Epie Boven
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2313-9.
1995: Hidde J Haisma; M Van Muijen; G Scheffer; R J Scheper; HERBERT PINEDO; Epie Boven
A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.
Hybridoma 1995;14(4):377-82.
1995: Boudewijn J M Braakhuis; Veronique Ruiz van Haperen; Epie Boven; Gijsbert Veerman; Godefridus J Peters
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Seminars in oncology 1995;22(4 Suppl 11):42-6.
1995: Henk J Broxterman; Nicole Feller; CM Kuiper; Epie Boven; C H Versantvoort; T Teerlink; HERBERT PINEDO; Jan Lankelma
Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts.
International journal of cancer. Journal international du cancer 1995;61(6):880-6.
1994: Veronique Ruiz van Haperen; Gijsbert Veerman; Epie Boven; Paul Noordhuis; Jan B Vermorken; Godefridus J Peters
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Biochemical pharmacology 1994;48(7):1327-39.
1994: WJ Jansen; HERBERT PINEDO; CM Kuiper; C Lincke; U Bamberger; A Heckel; Epie Boven
Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(8):733-9.
1994: Veronique Ruiz van Haperen; Gijsbert Veerman; S Eriksson; Epie Boven; A P Stegmann; M Hermsen; Jan B Vermorken; HERBERT PINEDO; Godefridus J Peters
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Cancer research 1994;54(15):4138-43.
1994: Simon P Langdon; HR Hendriks; Boudewijn J M Braakhuis; G Pratesi; Dietmar P Berger; Oystein Fodstad; Heinz-Herbert Fiebig; Epie Boven
Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(5):415-22.
1994: M Treskes; Epie Boven; A A van de Loosdrecht; J F Wijffels; J Cloos; Godefridus J Peters; HERBERT PINEDO; Wim J F van der Vijgh
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
European journal of cancer (Oxford, England : 1990) 1994;30A(2):183-7.
1994: Hidde J Haisma; M van Muijen; HERBERT PINEDO; Epie Boven
Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
Cell biophysics 1994;24-25():185-92.
1993: Jan C Roos; M A Plaizier; Arthur van Lingen; Hidde J Haisma; W den Hollander; H J Martens; J J Nauta; R L Dejager; Gerrit J J Teule; Epie Boven
Distribution and kinetics of 131I-labeled human IgM monoclonal antibody 16.88 in patients with advanced colorectal cancer.
In vivo (Athens, Greece) 1993;7(6A):503-9.
1993: Epie Boven; H Schipper; C A Erkelens; S A Hatty; HERBERT PINEDO
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
British journal of cancer 1993;68(1):52-6.
1993: Epie Boven; E Venema-Gaberscek; C A Erkelens; M C Bissery; HERBERT PINEDO
Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(4):321-4.
1993: HR Hendriks; P E Pizao; Dietmar P Berger; K L Kooistra; M C Bibby; Epie Boven; H C Dreef-van der Meulen; R E Henrar; Heinz-Herbert Fiebig; J A Double
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
European journal of cancer (Oxford, England : 1990) 1993;29A(6):897-906.
1993: Veronique Ruiz van Haperen; Gijsbert Veerman; Boudewijn J M Braakhuis; Jan B Vermorken; Epie Boven; A Leyva; Godefridus J Peters
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2132-7.
1992: Epie Boven; H R Hendriks; C A Erkelens; HERBERT PINEDO
The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.
British journal of cancer 1992;66(6):1044-7.
1992: Carla F M Molthoff; M R Buist; Peter Kenemans; HERBERT PINEDO; Epie Boven
Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(11):2000-5.
1992: Epie Boven; B Winograd; Dietmar P Berger; M P Dumont; Boudewijn J M Braakhuis; Oystein Fodstad; Simon P Langdon; Heinz-Herbert Fiebig
Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.
Cancer research 1992;52(21):5940-7.
1992: Hidde J Haisma; HERBERT PINEDO; C A Silva; Epie Boven
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies directed against intracellular antigens.
Journal of immunological methods 1992;154(1):55-60.
1992: Hidde J Haisma; Epie Boven; M van Muijen; J de Jong; W J van der Vijgh; HERBERT PINEDO
A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
British journal of cancer 1992;66(3):474-8.
1992: Carla F M Molthoff; HERBERT PINEDO; Hennie M M Schlüper; H W Nijman; Epie Boven
Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
British journal of cancer 1992;65(5):677-83.
1992: Carla F M Molthoff; HERBERT PINEDO; Hennie M M Schlüper; D H Rutgers; Epie Boven
Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts.
International journal of cancer. Journal international du cancer 1992;51(1):108-15.
1992: M Treskes; Epie Boven; U Holwerda; HERBERT PINEDO; Wim J F van der Vijgh
Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Cancer research 1992;52(8):2257-60.
1992: Carla F M Molthoff; HERBERT PINEDO; Hennie M M Schlüper; Epie Boven
Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model.
International journal of cancer. Journal international du cancer 1992;50(3):474-80.
1992: Hidde J Haisma; Epie Boven; M van Muijen; R De Vries; HERBERT PINEDO
Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.
Cancer immunology, immunotherapy : CII 1992;34(5):343-8.
1991: Hidde J Haisma; HERBERT PINEDO; M A Kessel; M van Muijen; J C Roos; M A Plaizier; H J Martens; R DeJager; Epie Boven
Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients.
Journal of the National Cancer Institute 1991;83(24):1813-9.
1991: K Hoekman; John Wagstaff; Cees J van Groeningen; J B Vermorken; Epie Boven; HERBERT PINEDO
Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.
Journal of the National Cancer Institute 1991;83(21):1546-53.
1991: J W Baars; John Wagstaff; Epie Boven; J B Vermorken; Cees J van Groeningen; Rik J Scheper; J C Fonk; H W Nijman; C R Franks; O Damsma
Phase I study on the sequential administration of recombinant human interferon-gamma and recombinant human interleukin-2 in patients with metastatic solid tumors.
Journal of the National Cancer Institute 1991;83(19):1408-10.
1991: I W Maas; Epie Boven; HERBERT PINEDO; Hennie M M Schlüper; Hidde J Haisma
The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines.
International journal of cancer. Journal international du cancer 1991;48(5):749-56.
1991: Carla F M Molthoff; J J Calame; HERBERT PINEDO; Epie Boven
Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression.
International journal of cancer. Journal international du cancer 1991;47(1):72-9.
1991: Epie Boven; Hidde J Haisma; H Bril; H J Martens; A van Lingen; W den Hollander; M A Kessel; R L DeJager; J C Roos
Tumour localisation with 131I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patients.
European journal of cancer (Oxford, England : 1990) 1991;27(11):1430-6.
1991: Carla F M Molthoff; HERBERT PINEDO; Hennie M M Schlüper; Epie Boven
Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian-cancer-bearing nude mice.
Cancer immunology, immunotherapy : CII 1991;34(3):191-7.
1990: Hidde J Haisma; M A Kessel; C Silva; M van Muijen; J C Roos; H Bril; H J Martens; R McCabe; Epie Boven
Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man.
The British journal of cancer. Supplement 1990;10():40-3.
1990: Epie Boven; C A M Erkelens; M Luning; HERBERT PINEDO
Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in human ovarian cancer lines.
British journal of cancer 1990;61(5):709-11.
1990: Epie Boven; Hennie M M Schlüper; C A Erkelens; HERBERT PINEDO
Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(9):983-6.
1989: Epie Boven; Hennie M M Schlüper; C A M Erkelens; M Luning; HERBERT PINEDO
A nude mouse-phase II model for human ovarian cancer.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):534-5.
1989: Epie Boven; J J Calame; Carla F M Molthoff; HERBERT PINEDO
Characterization and chemotherapy of human soft tissue sarcoma (STS) lines grown in nude mice.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):538-9.
1989: Carla F M Molthoff; Epie Boven; J J Calame; Peter J. van Beek; HERBERT PINEDO
Characterization of human ovarian cancer lines with a panel of monoclonal antibodies (MoAbs).
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):494-5.
1988: Epie Boven; A H Tierie; J Stam; HERBERT PINEDO
Combined radiation therapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer: results of a phase II trial.
Seminars in oncology 1988;15(6 Suppl 7):18-9.
1988: Epie Boven; B Winograd; O Fodstad; M W Lobbezoo; HERBERT PINEDO
Preclinical phase II studies in human tumor lines: a European multicenter study.
European journal of cancer & clinical oncology 1988;24(3):567-73.
1988: K Mross; P Maessen; Wim J F van der Vijgh; H Gall; Epie Boven; HERBERT PINEDO
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(3):517-26.
1987: G van Harskamp; Epie Boven; J B Vermorken; H van Deutekom; J Stam; K H Njo; A B Karim; A H Tierie; R P Golding; HERBERT PINEDO
Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC).
International journal of radiation oncology, biology, physics 1987;13(11):1735-8.
1987: B Winograd; Epie Boven; M W Lobbezoo; HERBERT PINEDO
Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).
In vivo (Athens, Greece) 1987;1(1):1-13.
1986: M M Nauta; Epie Boven; Hennie M M Schlüper; C A M Erkelens; HERBERT PINEDO
Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice.
British journal of cancer 1986;54(2):331-5.
1985: Epie Boven; M M Nauta; H M Schluper; F Elferink; Wim J F van der Vijgh; HERBERT PINEDO
Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
European journal of cancer & clinical oncology 1985;21(10):1253-60.
1985: Epie Boven; Wim J F van der Vijgh; M M Nauta; Hennie M M Schlüper; HERBERT PINEDO
Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Cancer research 1985;45(1):86-90.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.